The report focuses on "Nuclear
Medicine Market and Radiopharmaceuticals [SPECT/PET Radioisotopes
(Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications
(Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends
& Forecast to 2017"
The market of radiopharmaceuticals is dominated by diagnostic
radioisotopes, comprising of SPECT and PET radioisotopes. The lion’s
share of the SPECT market is taken up by Tc-99m, whereas the PET market
is dominated by F-18FDG isotope. Furthermore, the PET market will
witness a double digit growth during the forecast period. The
therapeutic segment contributes only 10% to the global
radiopharmaceuticals market and I-131 has been considered as the gold
standard for various oncology treatments in a combined therapy. Global
nuclear medicines market is majorly driven by the increasing adoption of
PET and SPECT scanners, and rising awareness for radiopharmaceuticals,
whereas short half life of isotopes and stringent regulations are the
factors that are hindering the growth of radiopharmaceuticals worldwide.
Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimer’s disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis.
North America held the largest share in the global radiopharmaceuticals market. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. China, India, Japan, South Korea, Brazil, and South Africa are expected to show a high growth potential amongst the emerging geographies. These countries are influenced by the domestic production of isotopes by reactors and government initiatives.
Apart from upcoming isotopes and their applications, understanding of the interlinked supply chain was imperative for market estimation. Value chain analysis and pipeline analysis have taken care of such business issues to come up with a consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.
The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals processors’ and generator manufacturer’s perspectives. It has been identified that shifting from HEU to LEU is the major strategy in the processors market, while strengthening the supply chain of radiopharmaceuticals is the prime concern for the generator manufacturers.
In addition to the market size and forecast for radioisotopes, the report also covers competitive landscape and key developments of major players, pipeline analysis, investment opportunities, and regulatory affairs for established players as well as new entrants.
The market of radiopharmaceuticals is dominated by diagnostic
radioisotopes, comprising of SPECT and PET radioisotopes. The lion’s
share of the SPECT market is taken up by Tc-99m, whereas the PET market
is dominated by F-18FDG isotope. Furthermore, the PET market will
witness a double digit growth during the forecast period. The
therapeutic segment contributes only 10% to the global
radiopharmaceuticals market and I-131 has been considered as the gold
standard for various oncology treatments in a combined therapy. Global
nuclear medicines market is majorly driven by the increasing adoption of
PET and SPECT scanners, and rising awareness for radiopharmaceuticals,
whereas short half life of isotopes and stringent regulations are the
factors that are hindering the growth of radiopharmaceuticals worldwide.Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimer’s disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis.
North America held the largest share in the global radiopharmaceuticals market. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. China, India, Japan, South Korea, Brazil, and South Africa are expected to show a high growth potential amongst the emerging geographies. These countries are influenced by the domestic production of isotopes by reactors and government initiatives.
Apart from upcoming isotopes and their applications, understanding of the interlinked supply chain was imperative for market estimation. Value chain analysis and pipeline analysis have taken care of such business issues to come up with a consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.
The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals processors’ and generator manufacturer’s perspectives. It has been identified that shifting from HEU to LEU is the major strategy in the processors market, while strengthening the supply chain of radiopharmaceuticals is the prime concern for the generator manufacturers.
In addition to the market size and forecast for radioisotopes, the report also covers competitive landscape and key developments of major players, pipeline analysis, investment opportunities, and regulatory affairs for established players as well as new entrants.
No comments:
Post a Comment